
Biotech Stock News: Prosensa Starts Rolling NDA Submission, Stock Reacts
Prosensa Holding N.V. (RNA) announced that it has initiated the process of rolling submission of a new drug application (NDA) to the FDA for its lead candidate, drisapersen, for the treatment of Duchenne muscular dystrophy (DMD). Drisapersen has Breakthrough Therapy Designation in the U.S. Moreover, the fast track status for drisapersen has made Prosensa eligible for making a rolling NDA submission for the candidate. According … Continue reading Biotech Stock News: Prosensa Starts Rolling NDA Submission, Stock Reacts